Blog

PASADENA, Calif., March 10, 2026 — AcuraStem, a patient-based biotechnology company developing disease- modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting SYF2, a recently identified regulator of TDP43 function. TDP-43 dysfunction is a central biological hallmark of ALS.